Forcing Face Masks Illegal And Is A Hazard To Your Health – Dr Russell Blaylock MD

“As to the cause of the headaches, while straps and pressure from the mask could be causative, the bulk of the evidence points toward hypoxia and/or hypercapnia as the cause. That is, a reduction in blood oxygenation (hypoxia) or an elevation in blood C02 (hypercapnia). It is known that the N95 mask, if worn for hours, can reduce blood oxygenation as much as 20%”

Forcing Face Masks Illegal And Unconstitutional!

I’ve been thinking about this a lot because my gut instincts were screaming “THIS IS ILLEGAL!!!” I’ve NEVER worn a mask, primarily for the reason I just mentioned. I also have never worn a mask because I don’t get sick…not from a Flu virus…I can’t remember the last time I was sick…

I was hospitalized last year a couple times, once because I fell and broke my shoulder and then another time after that, I fell and couldn’t get up…I completely exhausted myself and was on the floor for about 4 or 5 days, hallucinating like crazy…or maybe seeing things as they really are? I was hospitalized for 10 days…apparently if I was on the floor another day…no food, no water the whole time, I would have checked out…but it was nothing I hadn’t been through before.

Forcing Face Masks Illegal

I got this image from CitizensForFreeSpeech.org, they’re cards that they send to you when you join, so you show them to any roll-overs that say you have to wear a mask. They might be difficult to read because of the size, so here’s what they say:

Wearing A Face Mask Poses A Serious Health Risk To Me.

Under the Health Insurance Portability and Accountability Act (HIPAA). I am NOT required to disclose my medical conditions to you.

I am exempt from any local or state regulation mandating face-mask usage in public.

The Americans With Disabilities Act provides that organizations and businesses can be fined up to $75,000 for the first violation and $150,000 for any subsequent violation.

PLEASE PROVIDE THE NECESSARY CONSIDERATION TO AID THE BEARER IN THEIR UNIMPEDED EXERCISE OF THEIR LEGAL AND CONSTITUTIONAL RIGHTS.

1st Amendment

Amendmant 1 Sorce: https://www.law.cornell.edu/constitution/first_amendmentCongress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the people peaceably to assemble, and to petition the government for a redress of grievances.

What Wearing A Mask Symbolizes

crochet covid condoms

When you readily dawn a facemask, you are letting EVERYONE who sees you know, how easily you rolled over when it was recommended that you wear a mask that will only make you sick or sicker!

Wearing a cloth mask of ANY kind IS the same as using a crocheted condom during sex. It’s the same as getting chipped, which is what is going to happen if people don’t see that this is a precursor to illegally chipping everyone. They just want to see how many people will comply with something so ridiculous…you might as well put a fucking star on your chest. Ta-a-a-ake the Mahahahahsk off.

crochet sperm
Crochet Sperm – Wearing A Mask May Stop These, But A Virus? That’s A Negative Ghost-Rider!

Quote from Anthony Fauci: “If you’ve had a flu shot in the past 5 years, you will test positive for COVID-19”. Why is that you ask?? Because COVID-19 was in the flu vaccine that you got.

Dr. Anthony Fauci is the first person to identify, isolate and PATENT Spike Glycoprotein S-120. It was more likely that Fauci stole the discovery from a real doctor, like Dr Judy Mikovits.

Check out Dr Fauci’s patents. The Pirbright Institute is involved with them…Pirbright is funded by the Bill & Melinda Gates foundation. They all have their tentacles in everything.

Dr Russell Blaylock MD – Face-Masks Pose Serious Threats To The Healthy

With the advent of the so-called COVID-19 pandemic, we have seen a number of medical practices that have little or no scientific support as regards reducing the spread of this infection. One of these measures is the wearing of facial masks, either a surgical-type mask, bandana or N95 respirator mask.

Wearing A Mask Is A Health Hazard
Wearing A Mask Is A Health Hazard

When this pandemic began and we knew little about the virus itself or its epidemiologic behavior, it was assumed that it would behave, in terms of spread among communities, like other respiratory viruses. Little has presented itself after intense study of this virus and its behavior to change this perception.

This is somewhat of an unusual virus in that for the vast majority of people infected by the virus, one experiences either no illness (asymptomatic) or very little sickness. Only a very small number of people are at risk of a potentially serious outcome from the infection—mainly those with underlying serious medical conditions in conjunction with advanced age and frailty, those with immune compromising conditions and nursing home patients near the end of their lives. There is growing evidence that the treatment protocol issued to treating doctors by the Center for Disease Control and Prevention (CDC), mainly intubation and use of a ventilator (respirator), may have contributed significantly to the high death rate in these select individuals.

By wearing a mask, the exhaled viruses will not be able to escape and will concentrate in the nasal passages, enter the olfactory nerves and travel into the brain.
Russell Blaylock, MD

As for the scientific support for the use of face mask, a recent careful examination of the literature, in which 17 of the best studies were analyzed, concluded that, “ None of the studies established a conclusive relationship between mask/respirator use and protection against influenza infection.”1   Keep in mind, no studies have been done to demonstrate that either a cloth mask or the N95 mask has any effect on transmission of the COVID-19 virus. Any recommendations, therefore, have to be based on studies of influenza virus transmission. And, as you have seen, there is no conclusive evidence of their efficiency in controlling flu virus transmission.

Mask Mind Kontrol Ultra Device
Masks Are Mind Control Devices

It is also instructive to know that until recently, the CDC did not recommend wearing a face mask or covering of any kind, unless a person was known to be infected, that is, until recently. Non-infected people need not wear a mask. When a person has TB we have them wear a mask, not the entire community of non-infected. The recommendations by the CDC and the WHO are not based on any studies of this virus and have never been used to contain any other virus pandemic or epidemic in history.

Now that we have established that there is no scientific evidence necessitating the wearing of a face mask for prevention, are there dangers to wearing a face mask, especially for long periods? Several studies have indeed found significant problems with wearing such a mask. This can vary from headaches, to increased airway resistance, carbon dioxide accumulation, to hypoxia, all the way to serious life-threatening complications.

There is a difference between the N95 respirator mask and the surgical mask (cloth or paper mask) in terms of side effects. The N95 mask, which filters out 95% of particles with a median diameter >0.3 µm, because it impairs respiratory exchange (breathing) to a greater degree than a soft mask, and is more often associated with headaches. In one such study, researchers surveyed 212 healthcare workers (47 males and 165 females) asking about presence of headaches with N95 mask use, duration of the headaches, type of headaches and if the person had preexisting headaches.2

They found that about a third of the workers developed headaches with use of the mask, most had preexisting headaches that were worsened by the mask wearing, and 60% required pain medications for relief. As to the cause of the headaches, while straps and pressure from the mask could be causative, the bulk of the evidence points toward hypoxia and/or hypercapnia as the cause.

That is, a reduction in blood oxygenation (hypoxia) or an elevation in blood C02 (hypercapnia). It is known that the N95 mask, if worn for hours, can reduce blood oxygenation as much as 20%, which can lead to a loss of consciousness, as happened to the hapless fellow driving around alone in his car wearing an N95 mask, causing him to pass out, and to crash his car and sustain injuries. I am sure that we have several cases of elderly individuals or any person with poor lung function passing out, hitting their head. This, of course, can lead to death.

Proper Virus Mask & Improper Virus Maask
Proper Virus Mask & Improper Virus Maask

A more recent study involving 159 healthcare workers aged 21 to 35 years of age found that 81% developed headaches from wearing a face mask.3   Some had pre-existing headaches that were precipitated by the masks. All felt like the headaches affected their work performance.

Unfortunately, no one is telling the frail elderly and those with lung diseases, such as COPD, emphysema or pulmonary fibrosis, of these dangers when wearing a facial mask of any kind—which can cause a severe worsening of lung function. This also includes lung cancer patients and people having had lung surgery, especially with partial resection or even the removal of a whole lung.

While most agree that the N95 mask can cause significant hypoxia and hypercapnia, another study of surgical masks found significant reductions in blood oxygen as well. In this study, researchers examined the blood oxygen levels in 53 surgeons using an oximeter. They measured blood oxygenation before surgery as well as at the end of surgeries.The researchers found that the mask reduced the blood oxygen levels (pa02) significantly. The longer the duration of wearing the mask, the greater the fall in blood oxygen levels.

The importance of these findings is that a drop in oxygen levels (hypoxia) is associated with an impairment in immunity. Studies have shown that hypoxia can inhibit the type of main immune cells used to fight viral infections called the CD4+ T-lymphocyte. This occurs because the hypoxia increases the level of a compound called hypoxia inducible factor-1 (HIF-1), which inhibits

T-lymphocytes and stimulates a powerful immune inhibitor cell called the Tregs. . This sets the stage for contracting any infection, including COVID-19 and making the consequences of that infection much graver. In essence, your mask may very well put you at an increased risk of infections and if so, having a much worse outcome.5,6,7

People with cancer, especially if the cancer has spread, will be at a further risk from prolonged hypoxia as the cancer grows best in a microenvironment that is low in oxygen. Low oxygen also promotes inflammation which can promote the growth, invasion and spread of cancers.8,9  Repeated episodes of hypoxia has been proposed as a significant factor in atherosclerosis and hence increases all cardiovascular (heart attacks) and cerebrovascular (strokes) diseases.10

Blaylock Health Channel - Dr Russell Blaylock
Blaylock Health Channel – www.BlaylockHealthChannel.com

There is another danger to wearing these masks on a daily basis, especially if worn for several hours. When a person is infected with a respiratory virus, they will expel some of the virus with each breath. If they are wearing a mask, especially an N95 mask or other tightly fitting mask, they will be constantly rebreathing the viruses, raising the concentration of the virus in the lungs and the nasal passages. We know that people who have the worst reactions to the coronavirus have the highest concentrations of the virus early on. And this leads to the deadly cytokine storm in a selected number.

It gets even more frightening. Newer evidence suggests that in some cases the virus can enter the brain.11,12 In most instances it enters the brain by way of the olfactory nerves (smell nerves), which connect directly with the area of the brain dealing with recent memory and memory consolidation. By wearing a mask, the exhaled viruses will not be able to escape and will concentrate in the nasal passages, enter the olfactory nerves and travel into the brain.13

It is evident from this review that there is insufficient evidence that wearing a mask of any kind can have a significant impact in preventing the spread of this virus.

The fact that this virus is a relatively benign infection for the vast majority of the population and that most of the at-risk group also survive from an infectious disease and epidemiological standpoint, by letting the virus spread through the healthier population we will reach a herd immunity level rather quickly that will end this pandemic quickly and prevent a return next winter.

During this time, we need to protect the at-risk population by avoiding close contact, boosting their immunity with compounds that boost cellular immunity and in general, care for them.

One should not attack and insult those who have chosen not to wear a mask, as these studies suggest that is the wise choice to make.

References

  1. bin-Reza F et al. The use of mask and respirators to prevent transmission of influenza: A systematic review of the scientific evidence. Resp Viruses 2012;6(4):257-67.
  2. Zhu JH et al. Effects of long-duration wearing of N95 respirator and surgical facemask: a pilot study. J Lung Pulm Resp Res 2014:4:97-100.
  3. Ong JJY et al. Headaches associated with personal protective equipment- A cross-sectional study among frontline healthcare workers during COVID-19. Headache 2020;60(5):864-877.
  4. Bader A et al. Preliminary report on surgical mask induced deoxygenation during major surgery. Neurocirugia 2008;19:12-126.
  5. Shehade H et al. Cutting edge: Hypoxia-Inducible Factor-1 negatively regulates Th1 function. J Immunol 2015;195:1372-1376.
  6. Westendorf AM et al. Hypoxia enhances immunosuppression by inhibiting CD4+ effector T cell function and promoting Treg activity. Cell Physiol Biochem 2017;41:1271-84.
  7. Sceneay J et al. Hypoxia-driven immunosuppression contributes to the pre-metastatic niche. Oncoimmunology 2013;2:1 e22355.
  8. Blaylock RL. Immunoexcitatory mechanisms in glioma proliferation, invasion and occasional metastasis. Surg Neurol Inter 2013;4:15.
  9. Aggarwal BB. Nucler factor-kappaB: The enemy within. Cancer Cell 2004;6:203-208.
  10. Savransky V et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Resp Crit Care Med 2007;175:1290-1297.
  11. Baig AM et al. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020;11:7:995-998.
  12. Wu Y et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behavior, and Immunity, In press.
  13. Perlman S et al. Spread of a neurotropic murine coronavirus into the CNS via the trigeminal and olfactory nerves. Virology 1989;170:556-560.
dr russell blaylock
Dr Russell Blaylock

Dr. Russell Blaylock, M.D. is a nationally recognized board-certified neurosurgeon, health practitioner, author and lecturer. For over a quarter of a century, he practiced in the demanding field of neurosurgery in addition to having a nutritional practice. He recently retired from his neurosurgical duties to devote his full attention to nutritional studies and research. Dr. Blaylock has authored three books on nutrition and wellness: “Excitotoxins: The Taste That Kills,” “Health and Nutrition Secrets That Can Save Your Life” & “Natural Strategies for Cancer Patients.

Patents By “Inventor” Anthony S. Fauci

“There will be a surprise outbreak…”

“There is no doubt in anyone’s mind that the new administration will be faced with the challenges that their predecessors were faced with.”

Hemagglutinin Esterase -COVID-19 Scare

Hemagglutinin esterase is a glycoprotein that certain enveloped viruses possess and use as invading mechanism. HEs helps in the attachment and destruction of certain sialic acid receptors that are found on the host cell surface. Viruses that possess HEs include Influenza C virus, toroviruses, and coronaviruses.

Dr Anthony Fauci patents
1. Spike-Glycoprotein (S) 2. M-Protein 3. Hemagglutinin-Esterase Dimer (HE) 4. Envelope 5. RNA and N Protein 6. E-Protein
  • 1. Spike-Glycoprotein (S)
  • 2. M-Protein
  • 3. Hemagglutinin-Esterase Dimer (HE)
  • 4. Envelope
  • 5. RNA and N Protein
  • 6. E-Protein

If there’s anybody that still doesn’t think the COVID-19 scare isn’t a False Flag, The spikes that come out of the Coronavirus, that make it attach inside the lungs are called Spike Glycoproteins or S-proteins for short. The COVID-19 virus has S-protein 120 spikes. S-protein 120 is only found in one other virus known to man, HIV. This shows that Covid-19 was genetically modified and weaponized by the insertion of these HIV proteins. Now everyone thinks they need to wear masks because of Anthony Fauci’s domestic terrorism.

Dr Anthony Fauci Patents

Look at the dates of the patents below and watch the very short video of Dr Fauci prophesying the “surprise outbreak”, which turned out to be COVID-19

Use of antagonists of the interaction between HIV GP120 and α4β7 integrin

hiv host cell

Patent Number: 9896509
Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4β integrin, such as α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection.

In several examples, the α4β integrin antagonist is a monoclonal antibody that specifically binds to a α4β4, α4β1 or α4β7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4β integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

Type: Grant
Filed: August 3, 2016
Date of Patent: February 20, 2018

Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci


USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN

Publication Number: 20160333097
Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4β integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4β integrin antagonist is a monoclonal antibody that specifically binds to a α4β, α4β1 or α4β7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC.

Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4β integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.


Type: Application
Filed: August 3, 2016
Publication Date: November 17, 2016
Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci


Use of antagonists of the interaction between HIV GP120 and α4β7 integrin
Patent Number: 9441041
Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4β integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4β integrin antagonist is a monoclonal antibody that specifically binds to a α4β, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC.

Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4β integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.


Type: Grant
Filed: September 21, 2015
Date of Patent: September 13, 2016
Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors:
James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci


USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN

Publication Number: 20160075786
Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4β integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4β integrin antagonist is a monoclonal antibody that specifically binds to a α4β, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC.

Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4β integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.


Type: Application
Filed: September 21, 2015
Publication Date: March 17, 2016
Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Serv
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci


IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION

Publication Number: 20090285815
Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain.

The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.
Type: Application
Filed: March 21, 2008
Publication Date: November 19, 2009
Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci


Fusion protein including of CD4

Patent Number: 7368114
Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain.

The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.
Type: Grant
Filed: October 24, 2002
Date of Patent: May 6, 2008
Assignee: The United States of America as represented by the Department of Health and Human Services
Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci


HIV related peptides

Patent Number: 6911527
Abstract:
This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.
Type: Grant
Filed: January 7, 2000
Date of Patent: June 28, 2005
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors: Giuseppe Scala, Xueni Chen, Oren J. Cohen, Anthony S. Fauci


Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4

Publication Number: 20040265306
Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody or a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.
Type:
Application
Filed: July 27, 2004
Publication Date: December 30, 2004
Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci


Immunologic enhancement with intermittent interleukin-2 therapy
Publication Number: 20030180254
Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value.

This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
Type: Application
Filed: January 23, 2003
Publication Date: September 25, 2003
Applicant: The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services
Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci


Immunologic enhancement with intermittent interleukin-2 therapy
Patent Number: 6548055
Abstract:
A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value.

This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
Type: Grant
Filed: August 9, 2000
Date of Patent: April 15, 2003
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci


Immunologic enhancement with intermittent interleukin-2 therapy
Patent Number: 6190656
Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value.

This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
Type: Grant
Filed:
September 2, 1997
Date of Patent: February 20, 2001
Assignee: The United States of America as represented by the Department of Health and Human Services
Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci


Immunologic enhancement with intermittent interleukin-2 therapy
Patent Number: 5696079
Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value.

This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
Type: Grant
Filed: May 26, 1995
Date of Patent: December 9, 1997
Assignee: The United States of America as represented by the Department of Health and Human Services
Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

Dr Anthony Fauci Prophesying A Surprise Outbreak During President Trump’s Administration!

The Dr Fauci 2017 pandemic video from his keynote address at Georgetown University on Pandemic Preparedness 2017 and how President Trump will have to deal with a “surprise outbreak”. Would that surprise outbreak have anything to do with one of the patents you have for the virus YOU, Dr Fauci, created and like the HIV virus, YOU, Dr Fauci, let spread around the world!!??

Dr Anthony Fauci, Prophesying A Surprise Outbreak!!